Gilead Sciences, Inc. Registration Rights AgreementRegistration Rights Agreement • March 14th, 2003 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
Gilead Sciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the Purchaser (as defined herein) upon the terms set forth in the Purchase Agreement (as defined herein) its 2.00% Convertible Senior Notes due December 15, 2007 (the “Securities”). As an inducement to the Purchaser to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Purchaser thereunder, the Company agrees with the Purchaser for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
GILEAD WORLD MARKETS, LTD. and PPG TENOFOVIR DF MANUFACTURING SUPPLY AGREEMENTManufacturing Agreement • March 14th, 2003 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
THIS SUPPLY AGREEMENT (“Agreement”) is entered into as January 1, 2003 (the “Effective Date”), by and between PPG-Sipsy S.A.S., a French company having a place of business at Z.I. la Croix Cadeau, B.P. 79, 49242 Avrille Cedex, France (“PPG”) and Gilead World Markets, Ltd., a company operating under the laws of the Cayman Islands, having its principal place of business at Queensgate House, South Church Street, PO Box 1234GT, Grand Cayman (“GWM”). PPG and GWM may be referred to singly as “Party” and collectively as “Parties” in this Agreement.
